AMGN approaches its April 30 Q1 2026 earnings release with short interest on the rise and the stock under modest pressure — though the broader lending market tells a story of containment, not escalation.
Short sellers have been building positions into the print. SI % of free float climbed sharply on April 24 to 2.4%, up more than 13% on the week after oscillating between 2.1% and 2.3% through most of April. That follows a meaningful unwind from mid-March levels near 3.0%, so the recent uptick looks more like a tactical reload than a fresh conviction trade. Despite the jump in shares short, the borrow market remains loose — cost to borrow has eased to below 0.4% APR, down roughly 15% over the month, and utilization at 1.8% is well beneath its 52-week peak of 4.4%. The option market adds little directional alarm: the put/call ratio of 0.82 barely differs from its 20-day average of 0.81, suggesting options traders are not paying up for downside protection. Amgen closed at $340.18 on April 27, down about 2.9% on the week and 2.5% over the past month, lagging a mixed peer group — REGN managed to recover on the week while GILD dropped more than 5%.
The analyst community is broadly neutral on the name. A consensus of "Hold" with a mean target near $353 implies modest upside of around 2.4% from current levels — hardly a ringing endorsement. UBS raised its target to $400 earlier in April while maintaining a Buy, arguing that growth products and pipeline optionality justify the premium. Morgan Stanley, by contrast, carried an Equal-Weight with a $326 target, sitting below the current price and signalling that the risk/reward is roughly balanced. The bull case centres on pipeline catalysts — MariTide, the obesity asset, and olpasiran, the cardiovascular candidate — as potential upside drivers beyond the core franchise. Bears point to patent exposure on key products, limited near-term pipeline visibility, and the near-certainty that Q1 will be the weakest margin quarter of the year due to inventory build and generic competition on legacy lines. Piper Sandler's Overweight with a $432 target is the outlier on the optimistic side; the cluster of neutral-to-cautious ratings at $350 reflects where most of the Street has anchored.
One data point worth flagging is the concentration of insider selling in mid-March, when ten executives — including CEO Robert Bradway and the CFO — all sold shares on the same date at $366.21. These look like scheduled plan sales rather than conviction trades, given the uniform date and the low trade-significance scores attached. Nonetheless, the net 90-day insider position is positive when broader stock award activity is included, so the signal is mixed at best. Institutionally, the register is dominated by passive flows: Vanguard and BlackRock together hold nearly 19% of shares, and Capital Research added over 3 million shares in Q1. Active holders adding meaningfully into the quarter suggests no broad institutional exit ahead of the print.
The Q1 report will test whether product revenue from the newer franchises — and any updated commentary on MariTide's clinical path — can shift the narrative away from the well-worn story of biosimilar headwinds and toward a credible mid-decade growth bridge that the market has yet to price in.
See the live data behind this article on ORTEX.
Open AMGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
